Skip to main content
. 2021 Apr 10;13(8):1819. doi: 10.3390/cancers13081819
CI confidence interval
ctDNA circulating tumor DNA
ICIs immune-checkpoint inhibitors
IHC Immunohistochemistry
LDH lactate dehydrogenase
MDSC myeloid derived suppressor cells
MHC major histocompatibility complex
MM metastatic melanoma
NGS next-generation sequencing
NLR neutrophil to lymphocyte ratio
ORR objective response rate
RR response rate
SD standard deviation
TCR T-cell receptor
TMB tumor mutational burden